



QINGHAI BIOTECH PHARMACEUTICAL GROUP LIMITED

青海生物製藥集團有限公司

(Formerly known as "Kaisa Health Group Holdings Limited 佳兆業健康集團控股有限公司")

(前稱「Kaisa Health Group Holdings Limited 佳兆業健康集團控股有限公司」)

(Incorporated in Bermuda with limited liability)

(於百慕達註冊成立之有限公司)

(Stock Code 股份代號 : 876)

30 September 2026

Dear registered shareholder(s),

Qinghai Biotech Pharmaceutical Group Limited (the "Company") – Notice of Publication of Interim Report 2026 (the "Current Corporate Communication")

The Current Corporate Communication of the Company has been published in English and Chinese languages and is available on the website of the Company at www.qhpharma.com and website of HKEXnews at www.hkexnews.hk. For the shareholders who have selected to receive the Company's corporate communications (the "Corporate Communications") (Note 1) in printed version, enclosed is the Current Corporate Communication of the Company in both English and Chinese versions. If you have any difficulty in receiving or gaining access to the Current Corporate Communication posted on the Company's website for any reason, please send your request (specifying your name, address and request) by email at ada@kaisahealth.com or by notice in writing to the Company's Hong Kong branch share registrar (the "Share Registrar"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong. The Company will promptly upon receipt of your request send the Current Corporate Communication to you in printed form free of charge.

Arrangement of Electronic Dissemination of Corporate Communications

Pursuant to Rule 2.07 of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules"), the Company is writing to inform you that the Company has adopted electronic dissemination of Corporate Communications. Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.qhpharma.com and the HKEXnews website at www.hkexnews.hk, in place of printed copies. You will receive a notice of publication of Corporate Communication by post or through email in accordance with your indicated preference.

Notwithstanding the above, please note that actionable corporate communications (Note 2) as defined under the Listing Rules (the "Actionable Corporate Communications") will be sent to you individually in printed form or through email in accordance with your indicated preference, in addition to being made available electronically on the Company's website and the HKEXnews website.

Solicitation of electronic contact details

To ensure timely receipt of the latest Corporate Communications, the Company recommends you provide your email address by scanning your personalized QR code printed on the enclosed reply form (the "Reply Form"). Alternatively, you may sign and return the Reply Form to the Share Registrar, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong.

If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the Share Registrar, you may (i) be unable to receive any notifications regarding the publication of Corporate Communications; (ii) need to proactively check the Company's website and the HKEXnews website to keep up with the publication of Corporate Communications; and (iii) the Company will send the Actionable Corporate Communications in printed form in the future.

If you want to receive future Corporate Communications in printed form, please complete and return the enclosed Reply Form to the Share Registrar or send an email to ada@kaisahealth.com, specifying your name, address and request to receive future Corporate Communications in printed form. Please note that such request shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Should you have any queries relating to this letter, please contact the Company by sending an email to ada@kaisahealth.com.

By order of the Board
Qinghai Biotech Pharmaceutical Group Limited
Kwok Ying Shing
Chairman

Note 1: Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

Note 2: Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.

各位登記股東：

青海生物製藥集團有限公司（「本公司」） – 中期報告 2026（「本次公司通訊」）之發佈通知

本公司的本次公司通訊備有中、英文版本，並已上載於本公司網站 www.qhpharma.com 和披露易網站 www.hkexnews.hk，歡迎瀏覽。若閣下之前選擇收取本公司通訊（「公司通訊」）^(附註 1) 之印刷版本，現向閣下奉上英文及中文版本的本次公司通訊。閣下若因任何理由以致在收取或接收載於本公司網站上的本次公司通訊出現困難，閣下可將要求（註明閣下的姓名、地址及要求）以電郵方式發送到 ada@kaisahealth.com 或以書面方式郵寄至本公司的香港股份過戶登記分處（「股份過戶處」）香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。本公司將於接到閣下通知後，盡快向閣下免費發送有關本次公司通訊的印刷本。

以電子方式發佈公司通訊之安排

根據香港聯合交易所有限公司證券上市規則（「上市規則」）第 2.07 條，現謹此通知閣下，本公司已採用電子方式發佈公司通訊之安排。請注意，所有未來公司通訊的英文版和中文版將在本公司網站 www.qhpharma.com 和披露易網站 www.hkexnews.hk 上提供，以代替印刷本。閣下將會以郵寄方式或電子郵件形式（按閣下所作選擇）收取公司通訊的登載通知。

儘管有上述安排，請注意上市規則所定義的可供採取行動的公司通訊^(附註 2)（「可供採取行動的公司通訊」）登載於本公司網站和披露易網站之外，將按閣下所作選擇以印刷本或電子郵件形式個別發送予閣下。

徵集電子聯絡資料

為確保及時收到最新的公司通訊，本公司建議閣下透過掃描隨附之回條（「回條」）上列印的閣下個人專屬二維碼來提供閣下的電子郵件地址。或者，閣下也可以簽署回條並交回股份過戶處，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。

如果本公司沒有收到閣下的有效電子郵件地址，直至股份過戶處收到閣下有效的電子郵件地址前，閣下或將(i)無法收到任何有關發佈公司通訊的通知；(ii)需要主動查看本公司網站和披露易網站以留意公司通訊的發佈；及(iii)本公司未來將以印刷本形式發送可供採取行動的公司通訊。

若閣下希望收取未來公司通訊之印刷版，請填妥隨附之回條並交回股份過戶處，或發送電子郵件至 ada@kaisahealth.com，並註明閣下的姓名、地址以及收取未來公司通訊印刷版的要求。請注意，收取公司通訊印刷版之指示由收悉閣下指示當日起計一年內有效，此後將失效。

如閣下對本函件有任何疑問，請發送電子郵件至 ada@kaisahealth.com 查詢。

承董事會命
青海生物製藥集團有限公司
主席
郭英成

2026 年 9 月 30 日

附註 1：公司通訊是指本公司為向其任何證券持有人提供資訊或提醒其採取行動而發佈或將要發佈的任何文件，包括但不限於(a)董事報告、年度帳目以及審計報告副本以及(如適用)財務摘要報告；(b)中期報告及其中期報告摘要（如適用）；(c)會議通知；(d)上市文件；(e)通函；及(f)委任表格。

附註 2：可供採取行動的公司通訊指任何涉及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利或作出選擇的公司通訊。



當閣下寄回此回條時，請將郵寄標籤剪貼於信封上。
如在本港投寄，閣下無需支付郵費或貼上郵票。